title: Advancing antibody drug conjugation: from the laboratory to a clinically approved anticancer drug.
abstract: The concept of using monoclonal antibodies for delivering drugs to cancer cells has been explored for decades, with early work surrounding nonspecific targets and drugs with low potencies. These studies underscored the importance of critical parameters, such as antigen and tumor target selection, linker stability, drug potency, pharmacokinetics, and conjugation methodology, in developing effective antibody drug conjugates with acceptable safety profiles. Brentuximab vedotin represents the culmination of much research and development activities in which many of these parameters were addressed. This article provides an overview of many studies that led to the development of this highly active antibody drug conjugate.
authors.affiliation: Seattle Genetics Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA. Electronic address: nokeley@seagen.com.
authors.forename: Nicole M
authors.initials: NM
authors.lastname: Okeley
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Alley
authors.forename: Peter D
authors.initials: PD
authors.lastname: Senter
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
keywords: Chemotherapeutic; Drug delivery; Immunotherapy; Monoclonal antibody; Targeting; Tumor